Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Am J Hosp Palliat Care ; : 10499091231190063, 2023 Jul 25.
Artigo em Inglês | MEDLINE | ID: mdl-37491203

RESUMO

BACKGROUND: Patients, caregivers, and healthcare professionals often describe a "good death" as a pain-free process. However, many patients experience pain during their last weeks of life. Advance directives (ADs) are legally binding documents that allow individuals to express their wishes for end-of-life care which should include management of their pain. METHODS: An interprofessional team conducted a comprehensive analysis of ADs from all 50 states and the District of Columbia to assess the inclusion of language that reflects patients' wishes for pain relief at the end of life. RESULTS: Thirty-seven (73%) of the 51 entities examined reflected the prototypical directive, containing explicit instructions for withholding or withdrawing interventions that may prolong suffering rather than options for treating pain. Of these, 12 (24%) did not include the word "pain". Only 14 states (27%) provided clear guidance for managing pain. Unexpectantly, researchers found that 13 (25%) addressed the common fears of patients, caregivers, and healthcare teams when using opioids to relieve suffering, such as addiction, sedation, appetite, or respiratory suppression, and hastening death. CONCLUSION: The majority of ADs reviewed lacked clear and comprehensive measures for addressing pain relief. This deficiency may contribute to the undertreatment of pain and amplify the anxiety felt by patients, families, and healthcare providers when making end-of-life decisions. The results highlight the need for improvements in ADs to help ensure that patients' wishes regarding pain management are adequately addressed, documented and respected.

2.
Clin. transl. oncol. (Print) ; 25(5): 1297-1306, mayo 2023. ilus, graf
Artigo em Inglês | IBECS | ID: ibc-219514

RESUMO

Backgrounds 125I brachytherapy is effective in relieving cancer pain due to osteolytic bone metastases. However, fewer studies focused on painful osteoblastic bone metastases (OBMs), we conducted a retrospective study to evaluate the efficacy of 125I brachytherapy for the treatment of painful OBMs. Methods From April 2017 to April 2019, clinical data of a total of 65 patients with OBMs who underwent CT/cone beam CT -guided 125I brachytherapy were collected and analyzed. The primary study endpoints were technical success, relief of pain (RoP), and quality of life (QoL). The secondary study endpoints were treatment-related complications, local tumor control (LCR), and overall survival (OS). The logistic regression analysis was performed to predict RoP. Results Technical success rate was 100%. Visual analog scale scores and daily morphine consumption continuously decreased significantly at 2 weeks, 6 weeks, and 10 weeks (all P < 0.05). The RoP at 6 weeks was 84.62%. QoL presented improvement at 6 and 10 weeks. Only minor complications occurred in 12 patients (18.46%). LCR was 93.85% at 10 weeks. The OS was 29.80 months. Two factors were significantly associated with the RoP: max diameter (MD, < 3 cm vs. ≥ 3 cm, P = 0.019) and serum levels of bone alkaline phosphatase (B-ALP, ≥ 100 U/L vs. < 100 U/L, P = 0.016). Conclusions 125I brachytherapy is an effective treatment in relieving painful OBMs and improving patients’ QoL (AU)


Assuntos
Humanos , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/secundário , Braquiterapia/efeitos adversos , Dor/etiologia , Qualidade de Vida , Estudos Retrospectivos , Resultado do Tratamento
3.
Abdom Radiol (NY) ; 48(6): 2157-2166, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-37039850

RESUMO

PURPOSE: To evaluate the clinical efficacy of celiac plexus block (CPB) combined with 125I seeds implantation (ISI) for refractory epigastric pain from abdominal malignancies. METHODS: The data of 81 patients with refractory epigastric pain [visual analog scale (VAS) score ≥ 4] from abdominal malignancies were collected in this retrospective case-control study. Group A (n = 40) was treated with CPB alone, while Group B (n = 41) underwent CPB combined with ISI. The primary study endpoints were the VAS score, quality of life (QoL), and local tumor control (LTC) rate. The secondary endpoints were complications, progression-free survival (PFS), and overall survival (OS). RESULTS: The VAS scores at week 2 (T2), week 4 (T4), week 8 (T8), and week 12 (T12) in both groups were significantly lower compared with the pretreatment values (all P < 0.01). VAS scores in Group B showed a sustained decrease, especially for "mild pain" and "moderate pain," while the VAS scores in Group A rebounded at T8 and T12 (both P < 0.01). The QoL in Group B improved significantly from T4 until T12, which better than that at T12 in Group A (all P < 0.01). The LTC rates at T8 were 35.0% and 92.7% in Groups A and B, respectively, with a significant difference (P < 0.01). Group B had a slightly lower complication rate and a slightly longer median PFS/OS than group A, but neither was statistically different (P = 0.09 and P = 0.99, respectively). CONCLUSION: CPB combined with ISI performs more sustained pain relief (up to 12 weeks) compared to CPB alone, and ultimately improves the patients' QoL.


Assuntos
Neoplasias Abdominais , Plexo Celíaco , Humanos , Qualidade de Vida , Estudos Retrospectivos , Estudos de Casos e Controles , Plexo Celíaco/diagnóstico por imagem , Analgésicos Opioides/uso terapêutico , Dor Abdominal/etiologia , Neoplasias Abdominais/complicações , Neoplasias Abdominais/diagnóstico por imagem
4.
Clin Transl Oncol ; 25(5): 1297-1306, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-36472748

RESUMO

BACKGROUNDS: 125I brachytherapy is effective in relieving cancer pain due to osteolytic bone metastases. However, fewer studies focused on painful osteoblastic bone metastases (OBMs), we conducted a retrospective study to evaluate the efficacy of 125I brachytherapy for the treatment of painful OBMs. METHODS: From April 2017 to April 2019, clinical data of a total of 65 patients with OBMs who underwent CT/cone beam CT -guided 125I brachytherapy were collected and analyzed. The primary study endpoints were technical success, relief of pain (RoP), and quality of life (QoL). The secondary study endpoints were treatment-related complications, local tumor control (LCR), and overall survival (OS). The logistic regression analysis was performed to predict RoP. RESULTS: Technical success rate was 100%. Visual analog scale scores and daily morphine consumption continuously decreased significantly at 2 weeks, 6 weeks, and 10 weeks (all P < 0.05). The RoP at 6 weeks was 84.62%. QoL presented improvement at 6 and 10 weeks. Only minor complications occurred in 12 patients (18.46%). LCR was 93.85% at 10 weeks. The OS was 29.80 months. Two factors were significantly associated with the RoP: max diameter (MD, < 3 cm vs. ≥ 3 cm, P = 0.019) and serum levels of bone alkaline phosphatase (B-ALP, ≥ 100 U/L vs. < 100 U/L, P = 0.016). CONCLUSIONS: 125I brachytherapy is an effective treatment in relieving painful OBMs and improving patients' QoL.


Assuntos
Neoplasias Ósseas , Braquiterapia , Humanos , Qualidade de Vida , Braquiterapia/efeitos adversos , Estudos Retrospectivos , Dor/etiologia , Resultado do Tratamento , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/secundário
5.
Community Dent Oral Epidemiol ; 42(3): 254-62, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24117800

RESUMO

BACKGROUND: The aim was to assess the role of visit history factors between the age of 13 and 30 years on oral health-related impact. MATERIALS AND METHODS: In 1988-89, n=7,673 South Australian school children aged 13 years were sampled with n=4,604 children (60.0%) and n=4,476 parents (58.3%) returning questionnaires. In 2005-06, n=632 baseline study participants responded (43.0% response of those traced and living in Adelaide). Oral health impact was measured at age 30 years using OHIP-14. RESULTS: Multivariate regression showed that OHIP scores were significantly higher (P<0.05) for those with episodes of relief of pain visits once (ß=1.487) or two or more times (ß=2.883), and episodes of extraction once (ß=1.301) or two or more times (ß=3.172). Higher positive dental visit attitude scores were associated with lower OHIP scores (ß=-1.265), as were being male (ß=-0.637), having a job (ß=-1.555) and being tertiary educated (ß=-0.632). CONCLUSIONS: History of adverse dental events between the age of 13 and 30 years such as episodes of relief of pain visits and episodes of extraction was associated with higher impact of oral health problems at age 30 suggesting a cumulative effect.


Assuntos
Assistência Odontológica/estatística & dados numéricos , Saúde Bucal , Qualidade de Vida , Adolescente , Adulto , Feminino , Humanos , Masculino , Austrália do Sul , Inquéritos e Questionários
6.
Colomb. med ; 37(3): 242-246, jul.-sept. 2006. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-585824

RESUMO

La Organización Mundial de la Salud define el cuidado paliativo como el cuidado total y activo en aquellos pacientes que no responden a un tratamiento curativo. El control del dolor, otros síntomas y los problemas psicológicos, sociales y espirituales son de fundamental importancia. La meta del cuidado paliativo es brindar la mejor calidad de vida a los pacientes y a sus familias. En el cuidado paliativo es necesario el manejo multidisciplinario. Nuevas estrategias como rotación de opioides y sus diferentes vías de administración pueden ofrecer analgesia con pocos efectos adversos.


The World Health Organisation defines palliative care as the active total care of patients whose disease is not responsive to curative treatment. Control of pain, of other symptoms, and of psychological, social and spiritual problems, is paramount. The goal of palliative care is achievement of the best quality of life for patients and their families. Palliative care is necessarily multidisciplinary. New strategies such as the switching opioids and/or their route of administration may offer improved analgesia with fewer adverse effects, thus providing therapeutic alternatives for the clinical community.


Assuntos
Acetaminofen , Analgésicos , Analgésicos Opioides , Codeína , Hidromorfona , Morfina , Neoplasias/enfermagem , Neoplasias/terapia , Preparações Farmacêuticas , Tramadol
7.
Iatreia ; 11(1): 32-43, mar. 1998. ilus
Artigo em Inglês, Espanhol | LILACS | ID: lil-427907

RESUMO

El objetivo de esta revisión es discutir algunos aspectos de las terapias no farmacológicas para aliviar el dolor y el sufrimiento las cuales no han recibido la atención que merecen por parte del personal de la salud. Se incluyen elementos de la terapia física como el calor, el frío, el ejercicio, la neuroestimulación y la acupuntura; la terapia cognoscitiva y conductual con métodos como la educación, la retroalimentación, la relajación, la musicoterapia, la hipnosis, la distracción, la sustitución de pensamientos e imágenes y la terapia grupal y familiar. Se discuten aspectos de la asistencia espiritual y el tacto humanizado. Todo esto con el fin de lograr un acercamiento humanizado al hombre que sufre.


In this review the author discusses some aspectsof non-pharmacologic therapies for relief of painand suffering; both physical and psychologicalapproaches are included; the former include heatand cold applicatio", exercises, neurostimulationand acupuncture; the latter are education,biofeedback, relaxation, musictherapy, hypnosis,thought sustitution, images and group and familytherapy. Aiso discussed are spiritual assistanceand humanized touch. The goal of theseapproaches is to obtain proximity with the sufferinghuman being


Assuntos
Terapias Complementares , Clínicas de Dor , Cura Mental
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...